DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Arion D, Kaushik N, McCormick S, et al. Phenotypic mechanism
of HIV-1 resistance to 3′-azido-3′-deoxythymidine
(AZT): Increased polymerization processivity and enhanced
sensitivity to pyrophosphate of the mutant viral reverse transcriptase.
Biochemistry, 1998, 37:15908–15917.
Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery:
An advisory statement from the National Surgical
Infection Prevention Project. Clin Infect Dis, 2004, 38:
1706–1715.
Bulitta JB, Ly NS, Yang JC, et al. Development and qualification
of a pharmacodynamic model for the pronounced inoculum
effect of ceftazidime against Pseudomonas aeruginosa.
Antimicrob Agents Chemother, 2009, 53: 46–56.
Chow AT, Chen A, Lattime H, et al. Penetration of levofloxacin
into skin tissue after oral administration of multiple 750 mg
once-daily doses. J Clin Pharm Ther, 2002, 27:143–150.
Conte JE Jr, Golden JA, McIver M, Zurlinden E. Intrapulmonary
pharmacokinetics and pharmacodynamics of high-dose levofloxacin
in healthy volunteer subjects. Int J Antimicrob
Agents, 2006, 28:114–121.
Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose
gentamicin for Staphylococcus aureus bacteremia and endocarditis
is nephrotoxic. Clin Infect Dis, 2009, 48:713–721.
Craig WA. Pharmacokinetic/pharmacodynamic parameters:
Rationale for antibacterial dosing of mice and men. Clin Infect
Dis, 1998, 26:1–10.
Craig WA. Pharmacodynamics of antimicrobials: General concepts
and applications. In: Antimicrobial Pharmacodynamics
in Theory and Practice, 2nd ed. (Nightangle CH, Ambrose PG,
Drusano G.L, Murakawa T, eds.), Informa Healthcare USA,
New York, 2007, pp. 1–19.
Craig WA, Kunin CM. Significance of serum protein and tissue
binding of antimicrobial agents. Annu Rev Med, 1976, 27:
287–300.
DHHS Panel on Guidelines for the Prevention and Treatment of
Opportunistic Infections in HIV-Infected Adults and
Adolescents. Guidelines for Prevention and Treatment of
Opportunistic Infections in HIV-Infected Adults and
Adolescents. Available at: http://aidsinfo.nih.gov/contentfiles/
Adult_OI.pdf. Accessed February 15, 2009.
Eagle H, Fleishman R, Musselman AD. Effect of schedule of
administration on the therapeutic efficacy of penicillin; importance
of the aggregate time penicillin remains at effectively
bactericidal levels. Am J Med, 1950, 9:280–299.
Falagas ME, Makris GC, Dimopoulos G, Matthaiou DK.
Heteroresistance: A concern of increasing clinical significance?
Clin Microbiol Infect, 2008, 14:101–104.
Fluit AC, Schmitz FJ. Resistance integrons and super-integrons.
Clin Microbiol Infect, 2004, 10:272–288.
Gerna G, Lilleri D, Callegaro A, et al. Prophylaxis followed by
preemptive therapy versus preemptive therapy for prevention of
human cytomegalovirus disease in pediatric patients undergoing
liver transplantation. Transplantation, 2008, 86:163–166.
Gibaldi M, Perrier D. Pharmacokinetics, Marcel Dekker,
New York, 1975.
Giraud A, Matic I, Radman M, et al. Mutator bacteria as a risk
factor in treatment of infectious diseases. Antimicrob Agents
Chemother, 2002, 46:863–865.
Gumbo T. Integrating pharmacokinetics, pharmacodynamics and
pharmacogenomics to predict outcomes in antibacterial therapy.
Curr Opin Drug Discov Devel, 2008, 11:32–42.
Gumbo T, Drusano GL, Liu W, et al. Anidulafungin pharmacokinetics
and microbial response in neutropenic mice with disseminated
candidiasis. Antimicrob Agents Chemother, 2006,
50:3695–3700.
Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent
Mycobacterium tuberculosis killing and prevention of resistance
by rifampin. Antimicrob Agents Chemother, 2007a, 51:
3781–3788.
Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity
and resistance emergence: Integrating pharmacodynamics
and pharmacogenomics to predict efficacy in different ethnic
populations. Antimicrob Agents Chemother, 2007b, 51:
2329–2336.
Hanna GJ, D’Aquila RT. Clinical use of genotypic and phenotypic
drug resistance testing to monitor antiretroviral
chemotherapy. Clin Infect Dis, 2001, 32:774–782.
Happi CT, Gbotosho GO, Folarin OA, et al. Selection of
Plasmodium falciparum multidrug resistance gene 1 alleles in
asexual stages and gametocytes by artemether-lumefantrine in
Nigerian children with uncomplicated falciparum malaria.
Antimicrob Agents Chemother, 2009, 53:888–895.
Harshey RM, Ramakrishnan T. Purification and properties of
DNA-dependent RNA polymerase from Mycobacterium
tuberculosis H37RV. Biochim Biophys Acta, 1976, 432:49–59.
Hayden FG, Pavia AT. Antiviral management of seasonal and
pandemic influenza. J Infect Dis, 2006, 194 (suppl 2):
S119–S126.
Hertogs K, de Bethune MP, Miller V, et al. A rapid method for
simultaneous detection of phenotypic resistance to inhibitors
of protease and reverse transcriptase in recombinant human
immunodeficiency virus type 1 isolates from patients treated
with antiretroviral drugs. Antimicrob Agents Chemother, 1998,
42:269–276.
Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug
resistance testing in adult HIV-1 infection: 2008 recommendations
of an International AIDS Society-USA panel. Clin Infect
Dis, 2008, 47:266–285.
Hofmann-Thiel S, van Ingen J, Feldmann K, et al. Mechanisms
of heteroresistance to isoniazid and rifampin of Mycobacterium
tuberculosis in Tashkent, Uzbekistan. Eur Respir J, 2009,
33:368–374.
Hooper DC. Fluoroquinolone resistance among Gram-positive
cocci. Lancet Infect Dis, 2002, 2:530–538.
Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics
of micafungin in pediatric patients and implications
for antifungal dosing. Antimicrob Agents Chemother, 2007,
51:3714–3719.
Jumbe N, Louie A, Leary R, et al. Application of a mathematical
model to prevent in vivo amplification of antibiotic-resistant
bacterial populations during therapy. J Clin Invest, 2003,
112:275–285.
Jumbe NL, Louie A, Miller MH, et al. Quinolone efflux pumps
play a central role in emergence of fluoroquinolone resistance
in Streptococcus pneumoniae. Antimicrob Agents Chemother,
2006, 50:310–317.
Kiem S, Schentag JJ. Interpretation of antibiotic concentration
ratios measured in epithelial lining fluid. Antimicrob Agents
Chemother, 2008, 52:24–36.
Koch R. Die aetiologie der Milzbrand-Krankheit, begründet auf
die Entwicklungsgeschichte des Bacillus Anthracis. Beiträge
zur Biologie der Pflanzen, 1876, 2:277–310.
1379
CHAPTER 48
GENERAL PRINCIPLES OF ANTIMICROBIAL THERAPY